Cite
HARVARD Citation
McCarthy, E. et al. (2017). The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology. p. 1049. [Online].